HIV News and Research RSS Feed - HIV News and Research

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan announces U.S. launch of Amlodipine and Valsartan Tablets

Mylan N.V. today announced the U.S. launch of Amlodipine and Valsartan Tablets, 5 mg/160 mg, 5 mg/320 mg, 10 mg/160 mg, 10 mg/320 mg, which is the generic version of Novartis' Exforge Tablets. [More]
New approach allows researchers to trap and watch highly motile cells

New approach allows researchers to trap and watch highly motile cells

Optical imaging of highly motile cells or cells in suspension, such as bacterial systems, yeast cells, and immune cells, is a challenging task, in many cases it is just not possible. The human immunodeficiency virus (HIV), for example, can spread very efficiently from an infected T cell to an uninfected T cell through direct cell-cell contact. [More]
Effective therapy enables immune system recovery in majority of children

Effective therapy enables immune system recovery in majority of children

Most children with HIV who have low levels of a key immune cell eventually recover levels of this cell after they begin treatment, according to a new study conducted by researchers at UCLA and other institutions in the U.S. and Brazil. [More]
NYUCD receives NIH grant to develop POC test to detect HIV antibodies and viral RNA

NYUCD receives NIH grant to develop POC test to detect HIV antibodies and viral RNA

New York University College of Dentistry has received a sub-award in the amount of $335,000 from a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health to complete the development of a fully automated self-confirming assay that can simultaneously detect HIV/AIDS antibodies and viral RNA from the AIDS virus in a single specimen. [More]
New Ebola vaccine shows promise in first phase 1 clinical trial

New Ebola vaccine shows promise in first phase 1 clinical trial

Results from the first phase 1 trial of an Ebola vaccine based on the current (2014) strain of the virus are today published in The Lancet. Until now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. The results suggest that the new vaccine is safe, and provokes an immune response in recipients, although further long-term testing will be needed to establish whether it can protect against the Ebola virus. [More]
TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance, U.S. Fund for UNICEF partner to bring new TB treatments for children

TB Alliance has announced a new partnership with the U.S. Fund for UNICEF that will dramatically increase the scope and impact of child and maternal health programs around the world to include the diagnosis and treatment of pediatric tuberculosis (TB), a significant cause of child mortality. [More]

APM, HIV/AIDS Resource Center merge to strengthen response to HIV in Southeast Michigan

In order to strengthen the response to HIV in Southeast Michigan, AIDS Partnership Michigan and HIV/AIDS Resource Center have merged their organizations. Building on a history of collaboration and excellence, the merger of APM and HARC will ensure the sustainability of comprehensive HIV/AIDS prevention and care in their now 10-county area where 63% of people living with HIV reside. [More]
Mayo Clinic Center for Tuberculosis introduces new medical journal

Mayo Clinic Center for Tuberculosis introduces new medical journal

The Mayo Clinic Center for Tuberculosis, a regional training and consultation center at Mayo Clinic's campus in Rochester, Minn, is today launching a new medical journal, the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. [More]
GenVec reports record financial results for Q4 and fiscal year 2014

GenVec reports record financial results for Q4 and fiscal year 2014

GenVec, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014. For the year ended December 31, 2014, the company reported a net loss of $2.5 million, or $0.16 per share, compared with a net loss of $10.0 million, or $0.77 per share, for the year ended December 31, 2013. [More]
New report highlights the need for disclosing Alzheimer's diagnosis to patients

New report highlights the need for disclosing Alzheimer's diagnosis to patients

The Alzheimer's Association's 2015 Alzheimer's Disease Facts and Figures report, released today, found that only 45 percent of people with Alzheimer's disease or their caregivers say they were told the diagnosis by their doctor. [More]
Home-exercise plan for HIV patients

Home-exercise plan for HIV patients

In addition to antiretroviral medications, people with HIV may soon begin receiving a home exercise plan from their doctors, according to a researcher at Case Western Reserve University's Frances Payne Bolton School of Nursing. [More]
Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics' Stempeucel drug receives ATMP classification from EMA for treatment of TAO

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, announced today that the European Medicines Agency has granted Advanced Therapy Medicinal Product classification for its novel stem cell drug 'Stempeucel' which will be used for the treatment of Thromboangiitis Obliterans (TAO). [More]
Pathogen may cause high levels of virulence in closely-related hosts

Pathogen may cause high levels of virulence in closely-related hosts

When viruses such as influenza and Ebola jump from one species to another, their ability to cause harm can change dramatically, but research from the University of Cambridge shows that it may be possible to predict the virus's virulence by looking at how deadly it is in closely-related species. [More]
Royal Free London NHS Foundation Trust deploys OpenText to manage patient medical care records

Royal Free London NHS Foundation Trust deploys OpenText to manage patient medical care records

OpenText, the global leader in Enterprise Information Management (EIM), today announced that the Royal Free London NHS Foundation Trust has implemented OpenText Content Suite to store and manage digitised copies of patient medical care records. [More]
Healthcare systems miss life-saving treatments learnt on battlefield

Healthcare systems miss life-saving treatments learnt on battlefield

Trauma is responsible for more global deaths annually than HIV, malaria and tuberculosis combined. Yet healthcare systems in many countries are missing out on life-saving treatments learnt on the battlefield, according to a review by King's College London and published today in the Journal of the Royal Society of Medicine. [More]
IU researchers reveal how Toxoplasma parasites modify brain cells

IU researchers reveal how Toxoplasma parasites modify brain cells

Rodents infected with a common parasite lose their fear of cats, resulting in easy meals for the felines. Now IU School of Medicine researchers have identified a new way the parasite may modify brain cells, possibly helping explain changes in the behavior of mice -- and humans. [More]
Janssen announces acquisition of XO1

Janssen announces acquisition of XO1

Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired XO1 Limited, a privately held asset-centric virtual biopharmaceutical company founded to develop the anti-thrombin antibody ichorcumab. [More]
PaMZ drug regimen shows potential to improve treatment for MDR-TB

PaMZ drug regimen shows potential to improve treatment for MDR-TB

A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy and did so at a faster rate, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, designed to bring this regimen through the last stage of testing, has begun. [More]
American Cancer Society, World Lung Foundation unveil ‘The Tobacco Atlas, Fifth Edition’

American Cancer Society, World Lung Foundation unveil ‘The Tobacco Atlas, Fifth Edition’

The Tobacco Atlas, Fifth Edition ("The Atlas"), and its companion mobile app and website TobaccoAtlas.org, were unveiled today by the American Cancer Society and World Lung Foundation at the 16th World Conference on Tobacco or Health. [More]
Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma's SPI-026 granted FDA Orphan Drug Designation for treatment of PAH

Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced today that its lead compound tacrolimus (SPI-026) has been granted Orphan Drug Designation by the U.S. Food & Drug Administration for the treatment of pulmonary arterial hypertension (PAH). [More]
Advertisement
Advertisement